These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38162959)

  • 61. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.
    Ng OT; Marimuthu K; Koh V; Pang J; Linn KZ; Sun J; De Wang L; Chia WN; Tiu C; Chan M; Ling LM; Vasoo S; Abdad MY; Chia PY; Lee TH; Lin RJ; Sadarangani SP; Chen MI; Said Z; Kurupatham L; Pung R; Wang LF; Cook AR; Leo YS; Lee VJ
    Lancet Infect Dis; 2021 Mar; 21(3):333-343. PubMed ID: 33152271
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Epidemiological characteristics of respiratory viruses in hospitalized children during the COVID-19 pandemic in southwestern China.
    Zhu L; Luo T; Yuan Y; Yang S; Niu C; Gong T; Wang X; Xie X; Luo J; Liu E; Fu Z; Tian D
    Front Cell Infect Microbiol; 2023; 13():1142199. PubMed ID: 37153160
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vaccination as an alternative to non-drug interventions to prevent local resurgence of COVID-19.
    Pan J; Zhu W; Tian J; Liu Z; Xu A; Yao Y; Wang W
    Infect Dis Poverty; 2022 Mar; 11(1):36. PubMed ID: 35346382
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Differential impact of non-pharmaceutical public health interventions on COVID-19 epidemics in the United States.
    Liu X; Xu X; Li G; Xu X; Sun Y; Wang F; Shi X; Li X; Xie G; Zhang L
    BMC Public Health; 2021 May; 21(1):965. PubMed ID: 34020613
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of non-pharmaceutical interventions on circulating respiratory viruses during the COVID-19 pandemic in Turkey.
    Kırca F; Aydoğan S; Gozalan A; Güler E; Uyan Erten AZ; Özşen Uygur AS; Doğan A; Dinc B
    Ann Saudi Med; 2023; 43(3):143-153. PubMed ID: 37270680
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm?
    Oh KB; Doherty TM; Vetter V; Bonanni P
    Expert Rev Vaccines; 2022 Nov; 21(11):1541-1553. PubMed ID: 36039786
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023.
    Murphy TJ; Swail H; Jain J; Anderson M; Awadalla P; Behl L; Brown PE; Charlton CL; Colwill K; Drews SJ; Gingras AC; Hinshaw D; Jha P; Kanji JN; Kirsh VA; Lang ALS; Langlois MA; Lee S; Lewin A; O'Brien SF; Pambrun C; Skead K; Stephens DA; Stein DR; Tipples G; Van Caeseele PG; Evans TG; Oxlade O; Mazer BD; Buckeridge DL
    CMAJ; 2023 Aug; 195(31):E1030-E1037. PubMed ID: 37580072
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada.
    Vilches TN; Zhang K; Van Exan R; Langley JM; Moghadas SM
    Vaccine; 2021 Apr; 39(17):2360-2365. PubMed ID: 33812742
    [TBL] [Abstract][Full Text] [Related]  

  • 69. COVID-19 Vaccination and Public Health Countermeasures on Variants of Concern in Canada: Evidence From a Spatial Hierarchical Cluster Analysis.
    Adeyinka DA; Neudorf C; Camillo CA; Marks WN; Muhajarine N
    JMIR Public Health Surveill; 2022 May; 8(5):e31968. PubMed ID: 35486447
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Significant Relaxation of SARS-CoV-2-Targeted Non-Pharmaceutical Interventions Will Result in Profound Mortality: A New York State Modelling Study.
    Hoffman BU
    medRxiv; 2020 May; ():. PubMed ID: 32511495
    [TBL] [Abstract][Full Text] [Related]  

  • 71. SARS-CoV-2 transmission in opposition-controlled Northwest Syria: modeling pandemic responses during political conflict.
    Marzouk M; Alhiraki OA; Aguas R; Gao B; Clapham H; Obaid W; Altaleb H; Almhawish N; Rihawi H; Abbara A; Douedari Y; Hariri M; Howard N;
    Int J Infect Dis; 2022 Apr; 117():103-115. PubMed ID: 35123027
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following High-Risk Exposure.
    Andrejko KL; Pry J; Myers JF; Openshaw J; Watt J; Birkett N; DeGuzman JL; Barbaduomo CM; Dong ZN; Fang AT; Frost PM; Ho T; Javadi MH; Li SS; Tran VH; Wan C; Jain S; Lewnard JA;
    Clin Infect Dis; 2022 Aug; 75(1):e276-e288. PubMed ID: 34932817
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review.
    Nussbaumer-Streit B; Mayr V; Dobrescu AI; Chapman A; Persad E; Klerings I; Wagner G; Siebert U; Ledinger D; Zachariah C; Gartlehner G
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013574. PubMed ID: 33959956
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of air temperature and containment measures on mitigating the intrahousehold transmission of SARS-CoV-2: a data-based modelling analysis.
    Liu D; Tai Q; Wang Y; Pu M; Zhang L; Su B
    BMJ Open; 2022 Apr; 12(4):e049383. PubMed ID: 35396278
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of a vaccine passport on first-dose SARS-CoV-2 vaccine coverage by age and area-level social determinants of health in the Canadian provinces of Quebec and Ontario: an interrupted time series analysis.
    Anato JLF; Ma H; Hamilton MA; Xia Y; Harper S; Buckeridge D; Brisson M; Hillmer MP; Malikov K; Kerem A; Beall R; Wagner CE; Racine É; Baral S; Dubé È; Mishra S; Maheu-Giroux M
    CMAJ Open; 2023; 11(5):E995-E1005. PubMed ID: 37875315
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Initial health care costs for COVID-19 in British Columbia and Ontario, Canada: an interprovincial population-based cohort study.
    Tsui TCO; Zeitouny S; Bremner KE; Cheung DC; Mulder C; Croxford R; Del Giudice L; Lapointe-Shaw L; Mendlowitz A; Wong WWL; Perlis N; Sander B; Teckle P; Tomlinson G; Walker JD; Malikov K; McGrail KM; Peacock S; Kulkarni GS; Pataky RE; Krahn MD
    CMAJ Open; 2022; 10(3):E818-E830. PubMed ID: 36126976
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessing the progression of the COVID-19 pandemic in Canada using testing data and time-dependent reproduction numbers.
    Edjoc R; Atchessi N; Lien A; Smith BA; Gabrani-Juma I; Abalos C; Heisz M
    Can J Public Health; 2020 Dec; 111(6):926-938. PubMed ID: 33090361
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association between mobility, non-pharmaceutical interventions, and COVID-19 transmission in Ghana: A modelling study using mobile phone data.
    Gibbs H; Liu Y; Abbott S; Baffoe-Nyarko I; Laryea DO; Akyereko E; Kuma-Aboagye P; Asante IA; Mitjà O; ; Ampofo W; Asiedu-Bekoe F; Marks M; Eggo RM
    PLOS Glob Public Health; 2022; 2(9):e0000502. PubMed ID: 36962513
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of a large-scale event on SARS-CoV-2 cases and hospitalizations in the Netherlands, carnival seasons 2022 and 2023.
    Gorgels KMF; Dukers-Muijrers NHTM; Evers YJ; Hackert VH; Savelkoul PHM; Hoebe CJPA
    Public Health Pract (Oxf); 2024 Dec; 8():100523. PubMed ID: 39263240
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of non-pharmaceutical interventions on COVID-19 outcomes: A heterogeneous age-related generalisation of the SEIR model.
    Mendes JM; Coelho PS
    Infect Dis Model; 2023 Jun; 8(3):742-68. PubMed ID: 37366483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.